Amarin Corp Plc (AMRN)

[ziploc_1]

Apotex, Hickma, and DRL will compete for patients who are taking gV for very high triglycerides...(i.e. over 500 mgm/dcl)...It does not take a genius to see that their goal is to infringe with their "skinny label" on Amarin's R-IT patents for CVD patients.

There are not enough patients for ONE gV company to make to make ends meet from selling to the very high triglyceride segment of the EPA market(which is about 7% of the total EPA market--the other 93% being for CVD)...let alone for THREE gV companies to make ends meet.

Don't these corporate buccaneers have any shame?...Will they be able to continue infringing with impunity saying:"its not our fault"?

If its not the fault of these gV companies ,whose fault is it? ...Could the fault be a loophole in the HW law, which is not being applied in the way it was intended?